Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer

E. Atas, K. Berchtold, M. Schlederer, S. Prodinger, F. Sternberg, P. Pucci, C. Steel, JD. Matthews, ER. James, C. Philippe, K. Trachtová, AA. Moazzami, N. Artamonova, F. Melchior, T. Redmer, G. Timelthaler, EE. Pohl, SD. Turner, I. Heidegger, M....

. 2025 ; 24 (1) : 134. [pub] 20250505

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015799

Grantová podpora
DOC 59-B33 Austrian Science Fund
F83 Austrian Science Fund
DOC 59-B33 Austrian Science Fund

Prostate cancer (PCa) and Type 2 diabetes (T2D) often co-occur, yet their relationship remains elusive. While some studies suggest that T2D lowers PCa risk, others report conflicting data. This study investigates the effects of peroxisome proliferator-activated receptor (PPAR) agonists Bezafibrate, Tesaglitazar, and Pioglitazone on PCa tumorigenesis. Analysis of patient datasets revealed that high PPARG expression correlates with advanced PCa and poor survival. The PPARγ agonists Pioglitazone and Tesaglitazar notably reduced cell proliferation and PPARγ protein levels in primary and metastatic PCa-derived cells. Proteomic analysis identified intrinsic differences in mTORC1 and mitochondrial fatty acid oxidation (FAO) pathways between primary and metastatic PCa cells, which were further disrupted by Tesaglitazar and Pioglitazone. Moreover, metabolomics, Seahorse Assay-based metabolic profiling, and radiotracer uptake assays revealed that Pioglitazone shifted primary PCa cells' metabolism towards glycolysis and increased FAO in metastatic cells, reducing mitochondrial ATP production. Furthermore, Pioglitazone suppressed cell migration in primary and metastatic PCa cells and induced the epithelial marker E-Cadherin in primary PCa cells. In vivo, Pioglitazone reduced tumor growth in a metastatic PC3 xenograft model, increased phosho AMPKα and decreased phospho mTOR levels. In addition, diabetic PCa patients treated with PPAR agonists post-radical prostatectomy implied no biochemical recurrence over five to ten years compared to non-diabetic PCa patients. Our findings suggest that Pioglitazone reduces PCa cell proliferation and induces metabolic and epithelial changes, highlighting the potential of repurposing metabolic drugs for PCa therapy.

Center for Biomarker Research in Medicine GmbH Graz Austria

Center for Cancer Research Medical University of Vienna Vienna Austria

Center of Physiology and Pharmacology Department of Vascular Biology and Thrombosis Research Medical University of Vienna Vienna Austria

Central European Institute of Technology Masaryk University Brno 62500 Czech Republic

Christian Doppler Laboratory for Applied Metabolomics Medical University of Vienna Vienna Austria

Department of Biological Sciences and Pathobiology Unit of Physiology and Biophysics University of Veterinary Medicine Vienna Austria

Department of Biomedical Imaging and Image Guided Therapy Division of Nuclear Medicine Medical University of Vienna Vienna Austria

Department of Molecular Biology Umeå University Umea Sweden

Department of Molecular Sciences Swedish University of Agricultural Sciences 75007 Uppsala Sweden

Department of Nutritional Science University of Vienna Vienna Austria

Department of Pathology Medical University of Vienna Vienna Austria

Department of Urology Medical University of Innsbruck Innsbruck Austria

Division of Cellular and Molecular Pathology Department of Pathology University of Cambridge Cambridge UK

Faculty of Medicine Masaryk University Brno Czech Republic

Institute for Genetics Cologne Excellence Cluster of Cellular Stress Responses in Aging Associated Diseases Cologne Germany

Unit of Laboratory Animal Pathology Institute of Pathology University of Veterinary Medicine Vienna Vienna Austria

University of Vienna Vienna Austria

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015799
003      
CZ-PrNML
005      
20250731091234.0
007      
ta
008      
250708s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12943-025-02320-y $2 doi
035    __
$a (PubMed)40320521
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Atas, Emine $u Department of Pathology, Medical University of Vienna, Vienna, Austria. emine.atas@meduniwien.ac.at $u Christian Doppler Laboratory for Applied Metabolomics (CDL-AM), Medical University of Vienna, Vienna, Austria. emine.atas@meduniwien.ac.at $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria. emine.atas@meduniwien.ac.at
245    14
$a The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer / $c E. Atas, K. Berchtold, M. Schlederer, S. Prodinger, F. Sternberg, P. Pucci, C. Steel, JD. Matthews, ER. James, C. Philippe, K. Trachtová, AA. Moazzami, N. Artamonova, F. Melchior, T. Redmer, G. Timelthaler, EE. Pohl, SD. Turner, I. Heidegger, M. Krueger, U. Resch, L. Kenner
520    9_
$a Prostate cancer (PCa) and Type 2 diabetes (T2D) often co-occur, yet their relationship remains elusive. While some studies suggest that T2D lowers PCa risk, others report conflicting data. This study investigates the effects of peroxisome proliferator-activated receptor (PPAR) agonists Bezafibrate, Tesaglitazar, and Pioglitazone on PCa tumorigenesis. Analysis of patient datasets revealed that high PPARG expression correlates with advanced PCa and poor survival. The PPARγ agonists Pioglitazone and Tesaglitazar notably reduced cell proliferation and PPARγ protein levels in primary and metastatic PCa-derived cells. Proteomic analysis identified intrinsic differences in mTORC1 and mitochondrial fatty acid oxidation (FAO) pathways between primary and metastatic PCa cells, which were further disrupted by Tesaglitazar and Pioglitazone. Moreover, metabolomics, Seahorse Assay-based metabolic profiling, and radiotracer uptake assays revealed that Pioglitazone shifted primary PCa cells' metabolism towards glycolysis and increased FAO in metastatic cells, reducing mitochondrial ATP production. Furthermore, Pioglitazone suppressed cell migration in primary and metastatic PCa cells and induced the epithelial marker E-Cadherin in primary PCa cells. In vivo, Pioglitazone reduced tumor growth in a metastatic PC3 xenograft model, increased phosho AMPKα and decreased phospho mTOR levels. In addition, diabetic PCa patients treated with PPAR agonists post-radical prostatectomy implied no biochemical recurrence over five to ten years compared to non-diabetic PCa patients. Our findings suggest that Pioglitazone reduces PCa cell proliferation and induces metabolic and epithelial changes, highlighting the potential of repurposing metabolic drugs for PCa therapy.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    12
$a pioglitazon $x farmakologie $7 D000077205
650    12
$a nádory prostaty $x metabolismus $x farmakoterapie $x patologie $7 D011471
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a zvířata $7 D000818
650    12
$a PPAR gama $x agonisté $x metabolismus $7 D047495
650    _2
$a myši $7 D051379
650    12
$a hypoglykemika $x farmakologie $7 D007004
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a xenogenní modely - testy protinádorové aktivity $7 D023041
650    _2
$a mitochondrie $x metabolismus $x účinky léků $7 D008928
650    _2
$a pohyb buněk $x účinky léků $7 D002465
650    _2
$a metabolické přeprogramování $7 D000097784
655    _2
$a časopisecké články $7 D016428
700    1_
$a Berchtold, Kerstin $u University of Vienna, Vienna, Austria
700    1_
$a Schlederer, Michaela $u Department of Pathology, Medical University of Vienna, Vienna, Austria
700    1_
$a Prodinger, Sophie $u University of Vienna, Vienna, Austria
700    1_
$a Sternberg, Felix $u Department of Biological Sciences and Pathobiology, Unit of Physiology and Biophysics, University of Veterinary Medicine, Vienna, Austria $u Department of Nutritional Science, University of Vienna, Vienna, Austria
700    1_
$a Pucci, Perla $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK
700    1_
$a Steel, Christopher $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK
700    1_
$a Matthews, Jamie D $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK
700    1_
$a James, Emily R $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK
700    1_
$a Philippe, Cécile $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria
700    1_
$a Trachtová, Karolína $u Christian Doppler Laboratory for Applied Metabolomics (CDL-AM), Medical University of Vienna, Vienna, Austria $u Central European Institute of Technology, Masaryk University, Brno, 62500, Czech Republic
700    1_
$a Moazzami, Ali A $u Department of Molecular Sciences, Swedish University of Agricultural Sciences, 75007, Uppsala, Sweden
700    1_
$a Artamonova, Nastasiia $u Department of Urology, Medical University of Innsbruck, Innsbruck, Austria
700    1_
$a Melchior, Felix $u Department of Urology, Medical University of Innsbruck, Innsbruck, Austria
700    1_
$a Redmer, Torben $u Unit of Laboratory Animal Pathology, Institute of Pathology, University of Veterinary Medicine Vienna, Vienna, Austria
700    1_
$a Timelthaler, Gerald $u Center for Cancer Research, Medical University of Vienna, Vienna, Austria
700    1_
$a Pohl, Elena E $u Department of Biological Sciences and Pathobiology, Unit of Physiology and Biophysics, University of Veterinary Medicine, Vienna, Austria
700    1_
$a Turner, Suzanne D $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Heidegger, Isabel $u Department of Urology, Medical University of Innsbruck, Innsbruck, Austria
700    1_
$a Krueger, Marcus $u Institute for Genetics, Cologne Excellence Cluster of Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany
700    1_
$a Resch, Ulrike $u Center of Physiology and Pharmacology, Department of Vascular Biology and Thrombosis Research, Medical University of Vienna, Vienna, Austria
700    1_
$a Kenner, Lukas $u Department of Pathology, Medical University of Vienna, Vienna, Austria. lukas.kenner@meduniwien.ac.at $u Christian Doppler Laboratory for Applied Metabolomics (CDL-AM), Medical University of Vienna, Vienna, Austria. lukas.kenner@meduniwien.ac.at $u Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria. lukas.kenner@meduniwien.ac.at $u Unit of Laboratory Animal Pathology, Institute of Pathology, University of Veterinary Medicine Vienna, Vienna, Austria. lukas.kenner@meduniwien.ac.at $u Center for Biomarker Research in Medicine GmbH (CBmed), Graz, Austria. lukas.kenner@meduniwien.ac.at $u Department of Molecular Biology, Umeå University, Umea, Sweden. lukas.kenner@meduniwien.ac.at
773    0_
$w MED00008245 $t Molecular cancer $x 1476-4598 $g Roč. 24, č. 1 (2025), s. 134
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40320521 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091228 $b ABA008
999    __
$a ok $b bmc $g 2366558 $s 1252924
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 24 $c 1 $d 134 $e 20250505 $i 1476-4598 $m Molecular cancer $n Mol Cancer $x MED00008245
GRA    __
$a DOC 59-B33 $p Austrian Science Fund
GRA    __
$a F83 $p Austrian Science Fund
GRA    __
$a DOC 59-B33 $p Austrian Science Fund
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace